During the most recent episode of Mad Money, Jim Cramer opened the show by emphasizing just how much American companies ...

The former workers cited various reasons why they think Novo was cautious: its conservative culture and history of investing ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

5. In a blow to Eli Lilly’s Zepbound, CVS Caremark chose Novo Nordisk’s Wegovy as the preferred GLP-1 weight loss medication for its largest commercial template formularies. A CVS spokesperson said ...

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

The US drugmaker has stolen a march on Novo Nordisk by bringing a viable oral weight-loss medicine, orforglipron, into successful phase 3 clinical trials. An oral version is the holy grail for drugs ...

The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...